Lecanemab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lecanemab" in English language version.

refsWebsite

Global rank English rank

20web.archive.org

1^st place

10nih.gov

4^th place

6doi.org

2^nd place

5fda.gov

447^th place

338^th place

4prnewswire.com

406^th place

258^th place

2biogen.com

low place

2clinicaltrials.gov

5,225^th place

4,062^nd place

2theguardian.com

12^th place

11^th place

2bbc.com

20^th place

30^th place

2europa.eu

68^th place

117^th place

1nature.com

234^th place

397^th place

1yalemedicine.org

low place

1semanticscholar.org

11^th place

8^th place

1nytimes.com

7^th place

1cision.com

6,491^st place

6,248^th place

1tga.gov.au

3,984^th place

2,622^nd place

1gov.uk

432^nd place

278^th place

1alzheimersresearchuk.org

low place

1cnn.com

28^th place

26^th place

1biopharmadive.com

low place

1icer.org

low place

1handle.net

102^nd place

76^th place

alzheimersresearchuk.org

Taylor E (22 August 2024). "New Alzheimer's treatment, lecanemab, makes the headlines: what's next?". Alzheimer's Research UK. Archived from the original on 23 August 2024. Retrieved 23 August 2024.

bbc.com

Gallagher J (30 November 2022). "Alzheimer's drug lecanemab hailed as momentous breakthrough". BBC News Online. Archived from the original on 2 December 2022. Retrieved 30 November 2022.
Walsh F (22 August 2024). "Lecanemab: First drug to slow Alzheimer's too costly for NHS". www.bbc.com. Archived from the original on 23 August 2024. Retrieved 23 August 2024.

biogen.com

investors.biogen.com

"Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia". Biogen (Press release). 16 October 2024. Retrieved 14 November 2024.
"Lecanemab Confirmatory Phase 3 Clarity Ad Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer's Disease" (Press release). Biogen. 27 September 2022. Archived from the original on 27 September 2022. Retrieved 28 September 2022.

biopharmadive.com

Bell J (6 February 2023). "Eisai gives first glimpse into Alzheimer's drug launch". BiopharmaDive. Archived from the original on 12 February 2023. Retrieved 11 February 2023.

cision.com

news.cision.com

"Leqembi launched in South Korea". Cision (Press release). 6 December 2024. Retrieved 6 December 2024.

clinicaltrials.gov

"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)". ClinicalTrials.gov. 11 July 2022. Archived from the original on 28 September 2022. Retrieved 28 September 2022.
Clinical trial number NCT01767311 for "Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease" at ClinicalTrials.gov

cnn.com

Howard J, Goodman B (6 January 2023). "Alzheimer's drug lecanemab receives accelerated approval amid safety concerns". CNN. Archived from the original on 6 January 2023. Retrieved 11 January 2023.

doi.org

Kwon D (22 August 2024). "Debate rages over Alzheimer's drug lecanemab as UK limits approval". Nature. doi:10.1038/d41586-024-02720-y.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. (January 2023). "Lecanemab in Early Alzheimer's Disease". The New England Journal of Medicine. 388 (1). Massachusetts Medical Society: 9–21. doi:10.1056/nejmoa2212948. PMID 36449413. S2CID 254094094.
O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. (August 2008). "Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study". Archives of Neurology. 65 (8): 1091–1095. doi:10.1001/archneur.65.8.1091. PMC 3409562. PMID 18695059.
Liu KY, Villain N, Ayton S, Ackley SF, Planche V, Howard R, et al. (2 May 2023). "Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease". Brain Communications. 5 (3): fcad175. doi:10.1093/braincomms/fcad175. PMC 10306158. PMID 37389302.
Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, et al. (2014). "Perspectives on future Alzheimer therapies: amyloid-β protofibrils – a new target for immunotherapy with BAN2401 in Alzheimer's disease". Alzheimer's Research & Therapy. 6 (2): 16. doi:10.1186/alzrt246. PMC 4054967. PMID 25031633.
Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, et al. (March 2018). "The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death". Journal of Neuroinflammation. 15 (1): 98. doi:10.1186/s12974-018-1134-4. PMC 5875007. PMID 29592816.

europa.eu

ema.europa.eu

"Leqembi". European Medicines Agency (EMA). 5 August 2024. Archived from the original on 27 July 2024. Retrieved 22 August 2024.
"Leqembi recommended for treatment of early Alzheimer's disease". European Medicines Agency (EMA). 14 November 2024. Retrieved 14 November 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov

"FDA Grants Accelerated Approval for Alzheimer's Disease Treatment" (Press release). U.S. Food and Drug Administration (FDA). 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023. This article incorporates text from this source, which is in the public domain.
"FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval". U.S. Food and Drug Administration (FDA) (Press release). 6 July 2023. Archived from the original on 6 July 2023. Retrieved 6 July 2023. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Leqembi". U.S. Food and Drug Administration (FDA). 6 February 2023. Archived from the original on 9 July 2023. Retrieved 8 July 2023.
"Lecanemab Summary Review" (PDF). Center for Drug Evaluation and Research (CDER). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 7 January 2023. Retrieved 7 January 2023.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

gov.uk

"Lecanemab licensed for adult patients in the early stages of Alzheimer's disease". Medicines and Healthcare products Regulatory Agency. 22 August 2024. Archived from the original on 23 August 2024. Retrieved 23 August 2024.

handle.net

hdl.handle.net

World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl:10665/340680.

icer.org

"ICER Publishes Final Evidence Report on Lecanemab for Alzheimer's Disease" (Press release). Institute for Clinical and Economic Review. 17 April 2023. Archived from the original on 7 May 2023. Retrieved 7 May 2023.

nature.com

Kwon D (22 August 2024). "Debate rages over Alzheimer's drug lecanemab as UK limits approval". Nature. doi:10.1038/d41586-024-02720-y.

nih.gov

pubmed.ncbi.nlm.nih.gov

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. (January 2023). "Lecanemab in Early Alzheimer's Disease". The New England Journal of Medicine. 388 (1). Massachusetts Medical Society: 9–21. doi:10.1056/nejmoa2212948. PMID 36449413. S2CID 254094094.
O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. (August 2008). "Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study". Archives of Neurology. 65 (8): 1091–1095. doi:10.1001/archneur.65.8.1091. PMC 3409562. PMID 18695059.
Liu KY, Villain N, Ayton S, Ackley SF, Planche V, Howard R, et al. (2 May 2023). "Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease". Brain Communications. 5 (3): fcad175. doi:10.1093/braincomms/fcad175. PMC 10306158. PMID 37389302.
Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, et al. (2014). "Perspectives on future Alzheimer therapies: amyloid-β protofibrils – a new target for immunotherapy with BAN2401 in Alzheimer's disease". Alzheimer's Research & Therapy. 6 (2): 16. doi:10.1186/alzrt246. PMC 4054967. PMID 25031633.
Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, et al. (March 2018). "The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death". Journal of Neuroinflammation. 15 (1): 98. doi:10.1186/s12974-018-1134-4. PMC 5875007. PMID 29592816.

ncbi.nlm.nih.gov

O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. (August 2008). "Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study". Archives of Neurology. 65 (8): 1091–1095. doi:10.1001/archneur.65.8.1091. PMC 3409562. PMID 18695059.
Liu KY, Villain N, Ayton S, Ackley SF, Planche V, Howard R, et al. (2 May 2023). "Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease". Brain Communications. 5 (3): fcad175. doi:10.1093/braincomms/fcad175. PMC 10306158. PMID 37389302.
Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, et al. (2014). "Perspectives on future Alzheimer therapies: amyloid-β protofibrils – a new target for immunotherapy with BAN2401 in Alzheimer's disease". Alzheimer's Research & Therapy. 6 (2): 16. doi:10.1186/alzrt246. PMC 4054967. PMID 25031633.
Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, et al. (March 2018). "The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death". Journal of Neuroinflammation. 15 (1): 98. doi:10.1186/s12974-018-1134-4. PMC 5875007. PMID 29592816.

dailymed.nlm.nih.gov

"Leqembi – lecanemab injection, solution". DailyMed. 11 January 2023. Archived from the original on 15 January 2023. Retrieved 21 January 2023.

nytimes.com

Robbins R, Belluck P (27 September 2022). "Alzheimer's Drug Slows Cognitive Decline in Key Study". The New York Times. Archived from the original on 28 September 2022. Retrieved 28 September 2022.

prnewswire.com

"Leqembi launched in South Korea" (Press release). BioArctic. 27 November 2024. Retrieved 6 December 2024 – via PR Newswire.
"Leqembi approved in Mexico" (Press release). BioArctic. 4 December 2024. Retrieved 6 December 2024 – via PR Newswire.
"Eisai will request reconsideration of initial decision for lecanemab in Australia" (Press release). BioArctic. 16 October 2024. Retrieved 6 December 2024 – via PR Newswire.
"Eisai's Approach To U.S. Pricing For Leqembi (Lecanemab), a Treatment For Early Alzheimer's Disease, Sets Forth Our Concept Of "Societal Value Of Medicine" In Relation To "Price Of Medicine"" (Press release). Eisai. 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023 – via PR Newswire.

semanticscholar.org

api.semanticscholar.org

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. (January 2023). "Lecanemab in Early Alzheimer's Disease". The New England Journal of Medicine. 388 (1). Massachusetts Medical Society: 9–21. doi:10.1056/nejmoa2212948. PMID 36449413. S2CID 254094094.

tga.gov.au

"TGA's decision to not register lecanemab (Leqembi)". Therapeutic Goods Administration (TGA) (Press release). 15 October 2024. Retrieved 14 November 2024.

theguardian.com

Sample I (22 November 2022). "'This looks like the real deal': Are we inching closer to a treatment for Alzheimer's?". The Guardian. Archived from the original on 10 January 2023.
Devlin H (28 September 2022). "Success of experimental Alzheimer's drug hailed as 'historic moment'". The Guardian. Archived from the original on 28 September 2022.

web.archive.org

"Leqembi – lecanemab injection, solution". DailyMed. 11 January 2023. Archived from the original on 15 January 2023. Retrieved 21 January 2023.
"FDA Grants Accelerated Approval for Alzheimer's Disease Treatment" (Press release). U.S. Food and Drug Administration (FDA). 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023. This article incorporates text from this source, which is in the public domain.
"FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval". U.S. Food and Drug Administration (FDA) (Press release). 6 July 2023. Archived from the original on 6 July 2023. Retrieved 6 July 2023. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Leqembi". U.S. Food and Drug Administration (FDA). 6 February 2023. Archived from the original on 9 July 2023. Retrieved 8 July 2023.
"Lecanemab Summary Review" (PDF). Center for Drug Evaluation and Research (CDER). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 7 January 2023. Retrieved 7 January 2023.
"Lecanemab, the New Alzheimer's Treatment: 3 Things To Know". Yale Medicine. Archived from the original on 7 December 2023. Retrieved 7 December 2023.
"Lecanemab Confirmatory Phase 3 Clarity Ad Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer's Disease" (Press release). Biogen. 27 September 2022. Archived from the original on 27 September 2022. Retrieved 28 September 2022.
Robbins R, Belluck P (27 September 2022). "Alzheimer's Drug Slows Cognitive Decline in Key Study". The New York Times. Archived from the original on 28 September 2022. Retrieved 28 September 2022.
"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)". ClinicalTrials.gov. 11 July 2022. Archived from the original on 28 September 2022. Retrieved 28 September 2022.
Sample I (22 November 2022). "'This looks like the real deal': Are we inching closer to a treatment for Alzheimer's?". The Guardian. Archived from the original on 10 January 2023.
Gallagher J (30 November 2022). "Alzheimer's drug lecanemab hailed as momentous breakthrough". BBC News Online. Archived from the original on 2 December 2022. Retrieved 30 November 2022.
"Leqembi". European Medicines Agency (EMA). 5 August 2024. Archived from the original on 27 July 2024. Retrieved 22 August 2024.
Walsh F (22 August 2024). "Lecanemab: First drug to slow Alzheimer's too costly for NHS". www.bbc.com. Archived from the original on 23 August 2024. Retrieved 23 August 2024.
"Lecanemab licensed for adult patients in the early stages of Alzheimer's disease". Medicines and Healthcare products Regulatory Agency. 22 August 2024. Archived from the original on 23 August 2024. Retrieved 23 August 2024.
Taylor E (22 August 2024). "New Alzheimer's treatment, lecanemab, makes the headlines: what's next?". Alzheimer's Research UK. Archived from the original on 23 August 2024. Retrieved 23 August 2024.
Howard J, Goodman B (6 January 2023). "Alzheimer's drug lecanemab receives accelerated approval amid safety concerns". CNN. Archived from the original on 6 January 2023. Retrieved 11 January 2023.
"Eisai's Approach To U.S. Pricing For Leqembi (Lecanemab), a Treatment For Early Alzheimer's Disease, Sets Forth Our Concept Of "Societal Value Of Medicine" In Relation To "Price Of Medicine"" (Press release). Eisai. 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023 – via PR Newswire.
Bell J (6 February 2023). "Eisai gives first glimpse into Alzheimer's drug launch". BiopharmaDive. Archived from the original on 12 February 2023. Retrieved 11 February 2023.
"ICER Publishes Final Evidence Report on Lecanemab for Alzheimer's Disease" (Press release). Institute for Clinical and Economic Review. 17 April 2023. Archived from the original on 7 May 2023. Retrieved 7 May 2023.
Devlin H (28 September 2022). "Success of experimental Alzheimer's drug hailed as 'historic moment'". The Guardian. Archived from the original on 28 September 2022.

yalemedicine.org

"Lecanemab, the New Alzheimer's Treatment: 3 Things To Know". Yale Medicine. Archived from the original on 7 December 2023. Retrieved 7 December 2023.